Dechra Pharmaceuticals PLC Completion of Acquisition (7888E)
February 13 2018 - 9:59AM
UK Regulatory
TIDMDPH
RNS Number : 7888E
Dechra Pharmaceuticals PLC
13 February 2018
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS
RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION,
DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED
STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH
AFRICA, HONG KONG, SINGAPORE OR JAPAN OR ANY OTHER JURISDICTION IN
WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
PLEASE SEE THE IMPORTANT NOTICES WITHIN THIS ANNOUNCEMENT.
13 February 2018
Dechra Pharmaceuticals PLC ("Dechra")
Completion of Acquisition
Dechra is pleased to announce that the Acquisition of AST Farma
B.V. ("AST Farma") and Le Vet Beheer B.V. ("Le Vet") has now
completed. Admission of the 3,670,625 Consideration Shares is
expected on the 14 February 2018.
For further information contact:
--------------------------------------- --------------------
Dechra Pharmaceuticals PLC Tel: +44 (0) 1606
814 730
Ian Page, Chief Executive Officer
Richard Cotton, Chief Financial
Officer
e-mail: corporate.enquiries@dechra.com
Investec Bank plc (Sole Sponsor, Tel: +44 (0) 20
Bookrunner and Broker) 7597 5970
Chris Treneman / Daniel Adams
/ Jonathan Wynn / Neil Coleman
TooleyStreet Communications Limited Office: +44 (0)
121 309 0099
Fiona Tooley, Director Mobile: +44 (0)
7785 703 523
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and related products business. Its expertise is in the development,
manufacture and sales and marketing of high quality products
exclusively for veterinarians worldwide. The majority of its
products are focused on key therapeutic categories where it has
leading market positions, and many of its products are used to
treat medical conditions for which there is no other effective
solution or have a clinical or dosing advantage over competitor
products. For more information, please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
Trademarks
Dechra and the Dechra 'D' logo are registered Trademarks of
Dechra Pharmaceuticals PLC.
IMPORTANT NOTICES
This announcement is for information purposes only and is not
intended to and does not constitute, or form part of, any offer or
invitation to purchase, subscribe for or otherwise acquire or
dispose of, or any solicitation to purchase or subscribe for or
otherwise acquire or dispose of, any securities in any
jurisdiction. Persons needing advice should consult an independent
financial adviser. The information contained in this announcement
is not for release, publication or distribution to persons in any
jurisdiction where to do so might constitute a violation of local
securities laws or regulations.
The information contained in this announcement is for background
purposes only and does not purport to be full or complete. The
information in this announcement is subject to change without
notice.
Investec Bank plc ("Investec") is authorised by the Prudential
Regulatory Authority and regulated in the United Kingdom by the
Prudential Regulation Authority and the Financial Conduct Authority
and is acting exclusively for Dechra and no one else in connection
with the Acquisition, the content of this announcement and other
matters described in this announcement. Investec will not regard
any other person as their client in relation to the Acquisition,
the content of this announcement and other matters described in
this announcement and will not be responsible to anyone other than
Dechra for providing the protections afforded to their respective
clients or for providing advice to any other person in relation to
the Acquisition, the content of this announcement or any other
matters referred to in this announcement.
This announcement has been issued by and is the sole
responsibility of Dechra. No representation or warranty, express or
implied, is or will be made as to, or in relation to, and no
responsibility or liability is or will be accepted by Investec or
by any of its affiliates or agents as to, or in relation to, the
contents of this announcement, including its accuracy, completeness
or verification or for any other statement made or purported to be
made by it, or on behalf of it, Dechra or any other person in
connection with Dechra, the Acquisition or for any other written or
oral information made available to or publicly available to any
interested party or its advisers, and nothing in this announcement
should be read as a promise or representation in this respect,
whether or not to the past or the future. Each of Investec and its
affiliates and agents disclaims to the fullest extent permitted by
law all and any responsibility or liability whatsoever, whether
arising in tort, contract or otherwise, which it might otherwise
have in respect of this announcement or any such statement.
Neither the content of Dechra's website (or any other website)
nor the content of any website accessible from hyperlinks on
Dechra's website (or any other website) is incorporated into or
forms part of this announcement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQUOVVRWBAUAAR
(END) Dow Jones Newswires
February 13, 2018 10:59 ET (15:59 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024